Product Description
Betamethasone topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body) and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). Betamethasone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Intramuscular
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: LEO Pharma
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, China, Denmark, France, Germany, Italy, Mexico, Netherlands, New Zealand, Poland, Spain, Turkey, United States, Unknown Location
Active Clinical Trial Count: 16
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Bursitis|Candidiasis|Pain Unspecified|Psoriasis|Retinitis Pigmentosa|Rhinitis, Allergic|Synovitis|Tendinopathy
Phase 2: Fallopian Tube Cancer|Ovarian Cancer|Pain, Postoperative|Peritoneal Cancer|Sinusitis
Phase 1: Dermatitis, Atopic|Healthy Volunteers|Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12618000798268p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Oncology Unspecified|Healthy Volunteers |
2018-10-22 |
|||
2024-511411-25-00 |
MGT-RPGR-022 | P3 |
Active, not recruiting |
Retinitis Pigmentosa |
2029-12-19 |
2025-05-02 |
Treatments |
|
2016-000407-84 |
2016-000407-84 | P3 |
Active, not recruiting |
Pain Unspecified |
2018-04-13 |
2022-03-13 |
Treatments |
|
NCT05981118 |
PIPA - Dermavant | P3 |
Enrolling by invitation |
Psoriasis |
2026-07-01 |
8% |
2025-12-18 |
Primary Completion Date|Primary Endpoints |
2022-501415-14-00 |
21-01/ClotriBet-S | P3 |
Recruiting |
Candidiasis |
2025-12-01 |
2025-05-02 |
Treatments |
|
NCT07328022 |
SIL-30953-III-24(1) | P3 |
Completed |
Tendinopathy|Bursitis|Synovitis |
2025-08-20 |
3% |
2026-01-09 |
|
NCT06916884 |
DESCUBRA | P3 |
Recruiting |
Rhinitis, Allergic |
2025-05-11 |
41% |
2025-04-09 |
|
2022-502983-19-00 |
ZNâc3-005 | P2 |
Recruiting |
Peritoneal Cancer|Fallopian Tube Cancer|Ovarian Cancer |
2027-09-01 |
2025-05-02 |
Treatments |
|
NCT07131657 |
PF_002 | P2 |
Completed |
Pain, Postoperative |
2025-12-03 |
12% |
2026-01-13 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
NCT05882903 |
FESS | P2 |
Recruiting |
Sinusitis |
2025-06-01 |
12% |
2024-11-13 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06781632 |
RopiCloBet | P1 |
Completed |
Healthy Volunteers |
2025-02-20 |
88% |
2025-05-20 |
|
ACTRN12624000107527 |
ACTRN12624000107527 | P1 |
Not yet recruiting |
Psoriasis|Dermatitis, Atopic |
None |
2024-08-29 |
Start Date|Treatments|Trial Status |
|
ACTRN12624000621516 |
ACTRN12624000621516 | P1 |
Not yet recruiting |
Psoriasis|Dermatitis, Atopic |
None |
2024-08-29 |
Start Date|Treatments|Trial Status |
|
CTR20222869 |
CTR20222869 | P2 |
Completed |
Unknown |
2023-06-18 |
2025-06-01 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06863701 |
SIL-30953-III-23(1) | P3 |
Recruiting |
Unknown |
2026-12-31 |
39% |
2025-03-08 |
|
CTR20233982 |
CTR20233982 | P3 |
Active, not recruiting |
Unknown |
None |
2025-11-02 |
Patient Enrollment|Treatments|Trial Status |